Top Tweets for #LLDAS
#TYK2i #deucravacitinib
#RCT in #SLE
LTE of #PAISLEY #RCT PERSISTENT #LLDAS &#DORIS #remission over 3 more yrs post 1 yr RCT BUT ++dropouts
#POS0695 #EULAR2026 @RheumNow
Aiming for #DORIS #SLE #remission
Or #LLDAS in #SLE
Related to ⬆️survival
#deep outcome in RCTs
➡️archived in #deucravacitinib ph2 #LTE
&
ph3 #dapirolizumab & #obintuzimab
-achieved in #CAR-T trials in #lupus
POS0683, 1364, 0695, OP0338
& several 🚗 T abst
#EULAR2026 @RheumNow
🆕paper ⬆️ prednisone daily dose is associated with worse #PROs in #SLE patients who have already reached #LLDAS. We need to reduce prednisone, even in patients with #LLDAS. It was led by @Asinghrheum #AlmenaraLupusCohort and it was published at @jrheum https://t.co/Hs2m6q5cc3
✅ Discover how the #interferon signature status modulates disease #activity, #damage, #remission and #LLDAS attainment with treatment in a large international cohort of real-world patients with systemic #lupus ⬇️ Latest paper from the #SPOCS cohort!
https://t.co/AyKU9WOnDI
#SLE Welcome to the #T2T #rheumatology family
Aim for #LUPUS
#Low low disease activity score
#LLDAS
Clinical remission
Low MD global ex 0.5 out of 3
On
Little to no #prednisone
7.5 mg or even <5mg/day
For some Pts this is only aspirational
✅ Very grateful to #Bahrain Society of #Rheumatology for the opportunity to interact with colleagues from the #Gulf about Treat-to-Target #T2T in systemic #Lupus. Together we will discuss the value of #Remission & #LLDAS as well as the use of treatments, including biologics👌
#SLE
Toronto 13th #Rheumatology #Update
@MarkMatsos said
Clinical #remission in #lupus is v difficult to obtain in a trial
#LLDAS #low #disease #activity does occur more often
Ex with #belimumab #anifrolimumab and other therapies
remission rates in RCTs are a benchmark
Excited to share new data on #belimumab and it’s ability to induce DORIS #remission and #LLDAS in systemic #lupus erythematosus.
NEW RESEARCH—A post-hoc analysis of data from five RCTs showed that a higher proportion of patients with #SLE treated with #belimumab plus standard therapy attained DORIS #remission and #LLDAS compared with placebo plus standard therapy
https://t.co/eM1xstzvJz
NEW RESEARCH—A post-hoc analysis of data from five RCTs showed that a higher proportion of patients with #SLE treated with #belimumab plus standard therapy attained DORIS #remission and #LLDAS compared with placebo plus standard therapy
https://t.co/eM1xstzvJz
Golder et al. report that sustained #LLDAS >36 months offers the greatest protection against #SLE flares and damage.
Access our detailed slide summary today, only on the #LupusForum
https://t.co/JzRMeDRhxg
Learn more about the association of #LLDAS with improved outcomes in patients with #SLE this month, on the #LupusForum Publications Podcast.
Listen to expert discussion on this topic and more, completely free on the Forum today!
🔗https://t.co/uGqem0m6tD
How does sustained #LLDAS remission relate to damage accrual and flare rates in patients with #SLE?
Download our latest slide summary on the publication from Golder et al. on the #LupusForum to find out!
https://t.co/mQvnsMTsuZ
Great editorial about #LLDAS attainment and favorable outcomes in patients with recent onset #SLE from the Asia Pacific #Lupus Collaboration cohort by Prof. Graciela S. Alarcón (or Chela as she prefers to be called), a prominent #Peruvian #rheumatologist, emeritus professor at the University of #Birmingham, who continues to be active in research, collaborating with LFA, LCTC and the #GLADEL cohort.
Editorial
Low Disease Activity Early in the Course of Systemic Lupus Erythematosus
📖 https://t.co/vVuugTKmqy
#lupus #diseaseactivity #remission
In a new study by Golder et al., sustained #LLDAS for over 3 months significantly reduced damage accrual and flare rates in #SLE patients.
Find out more on #LupusForum today! https://t.co/WticXQU9vw
Prof @EricFMorand from @MonashUni reported no differences in accrual of damage and risk of flare for #lupus patients if redefining #LLDAS using 5mg prednisone instead of 7.5mg!
He conclude that lowering prednisone dose is a goal of #SLE management
#EULAR2024
MP
NEW RESEARCH—Protective associations of #LLDAS and remission on disease flares and damage accrual in #SLE incrementally increase with longer durations in the target state, with a threshold for protective effects of 3 months sustained LLDAS https://t.co/0qnuWWiLD4 @EricFMorand
Im generally not very good at making call-to-actions since im a nobody but i think @USTFMSofficial & SLMC should join because #LLDAS is one of the articles
@RHEUMarampa @RheumaRambolMD @elainesium_md @evanvistamd @GerRheumDoc @jm_thehermit @fayeesnow #RheumMadness
After attaining #remission or #LLDAS after a flare - HALF flare over f/u esp if tapering pred to <7.5 or 5 mg. #HCQ was protective. 65% got LLDAs and 45% rem in 1/2 yr - longer time to get #remission #2553 #ACR23 @RheumNow @ACRheum #ACRbest Asian cohort of #SLE largest@in world
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
240.2M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.4M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.6M followers
KATY PERRY
@katyperry
87M followers
Taylor Swift
@taylorswift13
80.9M followers
Lady Gaga
@ladygaga
72.4M followers
Kim Kardashian
@kimkardashian
69.5M followers
Virat Kohli
@imvkohli
68.9M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.5M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.5M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.1M followers